Unyvero Applications

Implant and tissue infections can be complex and time-consuming to diagnose. The treatment of patients with implant and tissue infections can only be optimized after microorganisms and associated resistances are known.

The Unyvero Implant & Tissue Infection (ITI) Cartridge tests for a total of 46 reportable targets (29 pathogens and 17 resistance genes). It delivers results with high sensitivity and specificity within just 4-5 hours. With this test panel, physicians can quickly diagnose infections and determine the optimum treatment in a matter of hours.

Worldwide, every 3 to 4 seconds a person succumbs to sepsis.¹ Sepsis continues to rise every year, and mortality rates are as high as 50%.^2,3 In industrialized countries, sepsis is already responsible for as many deaths as heart attacks. ⁴

The Unyvero Blood Culture (BCU) Cartridge for positive blood cultures tests for a total of 50 reportable targets (34 pathogens and 16 resistance genes) for a single sample. It delivers results with high sensitivity and specificity within just 4-5 hours.

¹WSD Fact Sheet 2018 (www.world-sepsis-day.org)
²Hotchkiss RS et al., Sepsis and septic shock. Nat Rev Dis Primers. 2016; 2:16045
³Fleischmann C et al., Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med. 2016; 193(3):259-72
⁴ Institut Pasteur, Disease Sheet -Sepsis, 2014

Intra-abdominal infections are the second most common cause of sepsis identified in intensive care units.^1,2 IAI is often associated with a poor prognosis, particularly in high-risk patients. With increasing rates of antibiotic resistance, the clinical picture can deteriorate rapidly. Early clinical diagnosis and appropriate antimicrobial therapy are essential in the management of intra-abdominal infections.³

The Unyvero Intra-Abdominal Infection (IAI) Cartridge tests for a total of 50 targets (26 pathogens, 2 toxins, and 22 resistance genes) with a sample-to-answer time of 4-5 hours. Based on this comprehensive analysis, physicians can quickly decide on the most appropriate treatment path, which improves outcomes, reduces length of inpatient stays, and lastly lowers healthcare costs.

¹Lopez N et al., A Comprehensive review of abdominal infections. World J Emerg Surg. 2011; 6:7
²Sartelli M et al., Current concept of abdominal sepsis: WSES position paper. World J Emerg Surg. 2014; 9:22
³Sartelli M et al., Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. World J Emerg Surg. 2017; 12:22

Complicated urinary tract infections are among the most prevalent hospital-acquired infections, and are the second most common cause of bacteremia in hospitalized patients.¹ The number of urinary tract infections caused by antibiotic-resistant bacteria is increasing.²

As with other serious infections, the key for effective treatment is the early diagnosis of pathogens and associated resistance markers. This allows targeted treatment, better use of available antibiotics, decreased length of hospital stays, and lower healthcare costs.

The Unyvero Urinary Tract Infection (UTI) Cartridge addresses this unmet clinical need with a broad panel of 40 reportable targets (25 pathogens and 15 resistance genes). In 4-5 hours, physicians can optimize treatment for their patients with severe UTIs.

¹Point prevalence survey: Acute care hospitals 2011-2012
²WHO. Prevention of hospital acquired infections: A practical guide. 2nd edition. 2002